Objective To evaluate the effectiveness of intralesional Bacille Calmette Guerin (BCG) immunotherapy in the treatment of warts in immunocompetent patients. Methods In our study, the sample size included 30 patients with multiple, recalcitrant, and recurrent warts. After taking informed consent, the patients were injected intralesionally with 0.1 ml BCG vaccine into the oldest wart at an interval of 3 weeks for a maximum of three sessions. Patients were evaluated every three weeks for a response, side effects and were followed up to 6 months for recurrences. For assessment of response, the grading scale was used. Results In our study, out of 30 patients, a good response was seen in 80%, while a partial response in 6.7%, and poor response in 13.3% of patients, and no recurrence was seen in 80% of patients in a follow-up of 6 months. In our study, 90% of patients had pain, 70% flu-like symptoms, 6.7% abscess, 6.7% ulceration, and 10% no adverse effects. Conclusion Intralesional BCG immunotherapy is a promising, simple, safe, and cost-effective modality for multiple, recalcitrant, and recurrent warts.